Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
Seagen Inc., Bothell, WA 98021, USA.
Future Oncol. 2024 Apr;20(12):749-760. doi: 10.2217/fon-2023-0358. Epub 2023 Sep 4.
To understand US physicians' frontline (1L) treatment preferences/decision-making for stage III/IV classic Hodgkin lymphoma (cHL). Medical oncologists and/or hematologists (≥2 years' practice experience) who treat adults with stage III/IV cHL were surveyed online (October-November 2020). Participants (n = 301) most commonly considered trial efficacy/safety data and national guidelines when selecting 1L cHL treatments. Most physicians (91%) rated overall survival (OS) as the most essential attribute when selecting 1L treatment. Variability was seen among regimen selection for hypothetical newly diagnosed patients, with OS cited as the most common reason for regimen selection. While treatment selection varied based on patient characteristics, US physicians consistently cited OS as the top factor considered when selecting a 1L treatment for cHL.
为了了解美国医生在治疗 III/IV 期经典霍奇金淋巴瘤（cHL）方面的一线（1L）治疗偏好/决策。对治疗 III/IV 期 cHL 成人的医学肿瘤学家和/或血液学家（≥2 年的实践经验）进行了在线调查（2020 年 10 月至 11 月）。参与者（n=301）在选择 1L cHL 治疗方法时最常考虑临床试验的疗效/安全性数据和国家指南。大多数医生（91%）在选择 1L 治疗时将总生存（OS）评为最重要的属性。在对假设的新诊断患者的方案选择中存在差异，OS 是选择方案的最常见原因。虽然治疗选择因患者特征而异，但美国医生一致认为 OS 是选择 cHL 一线治疗方案时最重要的考虑因素。
